XML 44 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated condensed statements of cash flows - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jul. 03, 2021
Jun. 27, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating activities:          
Net income $ 13,748 $ 4,506      
Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:          
Depreciation and amortization 14,663 14,513      
Change in fair value of contingent consideration 641 0      
Provision for expected credit losses (359) 1,162      
(Recovery) provision for expected credit losses (359) 1,162      
Equity-based compensation from 2021 Stock Incentive Plan 7,797 0      
Profits interest plan, liability-classified and other equity awards compensation (24,356) (6,771)      
Change in fair value of interest rate swap (1,310) 2,001      
Change in fair value of Equity Participation Rights unit (2,774) (788)      
Impairments related to variable interest entity 7,043 0      
Other, net (255) (134)      
Changes in operating assets and liabilities:          
Accounts receivable (9,370) 16,631      
Inventories 3,913 (6,329)      
Accounts payable and accrued expenses 2,917 1,587      
Other current assets and liabilities (13,011) (867)      
Net cash from operating activities (713) 25,511      
Investing activities:          
Purchase of Bioness, Inc, net of cash acquired (45,790) 0      
Purchase of property and equipment (2,642) (1,050)      
Other (864) (152)      
Net cash from investing activities (49,296) (1,202)      
Net cash from investing activities - discontinued operations 0 172      
Net cash from investing activities (49,296) (1,030)      
Financing activities:          
Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs 107,777 0      
Proceeds from issuance of Class A and B common stock 330 0      
Borrowing on revolver 0 49,000      
Payments on long-term debt (7,500) (2,500)      
Refunds (distributions) - members 813 (9,075)      
Other, net (11) 0      
Net cash from financing activities 101,409 37,425 $ (29,569) $ (10,951) $ (13,256)
Effect of exchange rate changes on cash (171) (186) 589 (104) (160)
Net change in cash, cash equivalents and restricted cash 51,229 61,720      
Cash, cash equivalents and restricted cash at the beginning of the period 86,839 64,520 64,520    
Cash, cash equivalents and restricted cash at the end of the period 138,068 126,240 86,839 64,520  
Supplemental disclosure of noncash investing and financing activities          
Accounts payable for purchase of property and equipment 695 14      
Accrued member distributions 305 787      
Bio Ventus LLC [Member]          
Operating activities:          
Net income     14,722 6,298 (12,207)
Net loss from discontinued operations       1,815 16,650
Net income from continuing operations     14,722 8,113 4,443
Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:          
Depreciation and amortization     28,643 30,316 29,238
Loss on impairment of intangible assets         489
Change in fair value of contingent consideration         (739)
Payment of contingent consideration in excess of amount established in purchase accounting       (945) (3,558)
Provision for expected credit losses     1,215 2,242 2,538
(Recovery) provision for expected credit losses     1,215 2,242 2,538
Profits interest plan, liability-classified and other equity awards compensation     10,103 10,844 14,325
Change in fair value of interest rate swap     1,599    
Deferred income taxes     (511) (348) (79)
Amortization of debt discount and capitalized loan fees, net     543 1,583 1,686
Loss on debt retirement and modification       3,352  
Change in fair value of Equity Participation Rights unit     644 565 1,009
Other, net     (67) 395 106
Changes in operating assets and liabilities:          
Accounts receivable     (3,941) (14,909) (12,130)
Inventories     (528) (1,427) 3,256
Accounts payable and accrued expenses     20,510 6,646 12,148
Other current assets and liabilities     (733) (3,882) (422)
Net cash provided by operating activities from continuing operations     72,199 42,545 52,310
Net cash used in operating activities of discontinued operations     (400) (1,832) (7,123)
Net cash from operating activities     71,799 40,713 45,187
Investing activities:          
Investment and acquisition of distribution rights     (16,579) (6,000) (3,500)
Acquisition of VIE       430  
Purchase of property and equipment     (4,093) (2,342) (2,561)
Net cash from investing activities     (20,672) (7,912) (6,061)
Net cash from investing activities - discontinued operations     172   (40)
Net cash from investing activities     (20,500) (7,912) (6,101)
Financing activities:          
Borrowing on revolver     49,000    
Payment on revolver     (49,000)    
Proceeds from the issuance of long-term debt, net of issuance costs       198,134  
Payments on long-term debt     (10,000) (199,500) (5,250)
Refunds (distributions) - members     (19,886) (9,137) (7,846)
Other, net     317 (448) (160)
Net change in cash, cash equivalents and restricted cash     22,319 21,746 25,670
Cash, cash equivalents and restricted cash at the beginning of the period $ 86,839 $ 64,520 64,520 42,774 17,104
Cash, cash equivalents and restricted cash at the end of the period     86,839 64,520 42,774
Supplemental disclosure of cash flow information          
Cash paid for income taxes     1,541 1,577 1,944
Cash paid for interest     7,486 15,450 17,273
Supplemental disclosure of noncash investing and financing activities          
Accrued liabilities for distribution rights     1,000   6,000
Debt conversion     973    
Accounts payable for purchase of property and equipment     336 34 184
Accrued member distributions     $ 31 $ 499 $ 906